Slingshot Biosciences aims to bring simple, elegant, and cost-effective solutions to common problems facing research and development programs. Our technology platform will make a significant bottom-line impact on the speed and cost of early-stage discovery, research and development programs.
Orbital Therapeutics is focused on advancing global health through the development of RNA-based medicines aimed at treating various human diseases. The company is building an innovative platform that integrates established and emerging technologies, delivery mechanisms, and data analytics to create a diverse portfolio of therapeutics. Their efforts encompass a wide range of applications, including vaccines, immunomodulation, protein replacement, and regenerative medicine. By harnessing the full potential of RNA technology, Orbital Therapeutics seeks to provide patients with modern treatment options that were previously unavailable, thus enhancing the efficacy and accessibility of medical therapies.
Nutcracker Therapeutics, Inc. is a biotechnology company focused on developing mRNA therapeutics using a proprietary microfluidic platform. Established in 2017 and based in Emeryville, California, the company specializes in a fully integrated system that allows for the on-demand production of mRNA therapeutics through its ACORN platform. This innovative, computer-controlled RNA manufacturing system utilizes a nucleic acid sequence to produce optimized, nanoparticle-encapsulated RNA therapeutics on single-use biochips. Nutcracker Therapeutics aims to enhance the scalability and efficiency of mRNA production, enabling healthcare companies to create complex multimodal therapeutics at the point of care. By combining advances in RNA biology with semiconductor manufacturing techniques, the company seeks to streamline the discovery, development, and manufacturing processes for mRNA therapies and vaccines.
Oxford NanoImaging Limited specializes in the development and manufacture of advanced microscopy tools for life sciences research. The company's flagship product, the Nanoimager, is a single-molecule fluorescence microscope designed to detect biomolecules, including disease-related protein markers and pathogens, at single copy numbers. This innovative microscope features capabilities such as 3D imaging and dual-color super-resolution, enhancing researchers' ability to study complex biological processes. In addition to the Nanoimager, Oxford NanoImaging offers various microscopy technologies, including Förster Resonance Energy Transfer microscopy, direct stochastic optical reconstruction microscopy, and photoactivated localization microscopy. Founded in 2016 and headquartered in London, with an additional office in Menlo Park, California, the company aims to make life science tools and knowledge accessible to a wider audience.
Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.
Slingshot Biosciences aims to bring simple, elegant, and cost-effective solutions to common problems facing research and development programs. Our technology platform will make a significant bottom-line impact on the speed and cost of early-stage discovery, research and development programs.
Locanabio, Inc. develops RNA-targeted gene therapies to treat a spectrum of underserved diseases. It offers therapies for neuromuscular, neurodegeneration, and ophthalmology diseases. Locanabio, Inc. was formerly known as Locana, Inc. and changed its name to Locanabio, Inc. in July 2020. The company was founded in 2016 and is based in San Diego, California.
SciNeuro Pharmaceuticals develops medicines for patients with central nervous system (CNS) diseases. The company is based in Shanghai, China.
Nutcracker Therapeutics, Inc. is a biotechnology company focused on developing mRNA therapeutics using a proprietary microfluidic platform. Established in 2017 and based in Emeryville, California, the company specializes in a fully integrated system that allows for the on-demand production of mRNA therapeutics through its ACORN platform. This innovative, computer-controlled RNA manufacturing system utilizes a nucleic acid sequence to produce optimized, nanoparticle-encapsulated RNA therapeutics on single-use biochips. Nutcracker Therapeutics aims to enhance the scalability and efficiency of mRNA production, enabling healthcare companies to create complex multimodal therapeutics at the point of care. By combining advances in RNA biology with semiconductor manufacturing techniques, the company seeks to streamline the discovery, development, and manufacturing processes for mRNA therapies and vaccines.
Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.
Glympse Bio, Inc. is focused on developing innovative diagnostic solutions that facilitate noninvasive monitoring of various diseases, including cancer, fibrosis, immunological disorders, and infectious diseases. The company employs modular nanoparticle sensors, utilizing precisely engineered diagnostic agents that assess disease states within the body and convey this information through urine analysis. This approach allows for predictive monitoring and evaluation of treatment responses. Founded in 2015 and based in Cambridge, Massachusetts, Glympse Bio's technology is rooted in research originally conducted at MIT and led by a team of experts in nanomedicine and biomedical engineering. Their flagship product, Glympse Inside, serves as a comprehensive platform for disease monitoring and aims to revolutionize how diseases are diagnosed and managed.
Sana Biotechnology is a biotechnology company focused on developing engineered cells as therapies for various diseases. Incorporated in 2018 and based in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company leverages recent scientific advancements to reprogram cells or replace damaged cells and tissues. Sana's mission is to create a new class of medicines that address unmet treatment needs across a wide range of therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Its pipeline includes several product candidates, such as SC291, SC262, SC255, and UP421, aimed at transforming the approach to disease treatment.
Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing induced pluripotent stem cell therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company aims to create patient-specific restorative cell therapies that can alter the progression of the disease. Its product pipeline includes ANPD001, an autologous neuron replacement therapy designed for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By integrating innovative genomic approaches with stem cell biology, Aspen Neuroscience seeks to advance the field of personalized medicine and improve treatment outcomes for patients suffering from Parkinson's disease.
Omniome, Inc. is a biotechnology company based in San Diego, California, established in 2013. It specializes in developing a proprietary DNA sequencing platform that aims to deliver high accuracy in sequencing results. The company employs its Sequencing By Binding technology, which enhances nucleotide and DNA matching by utilizing the natural matching capabilities of polymerase. This innovative approach not only provides precise and rapid results but also offers a cost-effective solution, which has the potential to significantly advance cancer diagnostics. Omniome is backed by prominent life sciences venture investors and is focused on becoming a trusted leader in the field of clinical sequencing.
Aspen Neuroscience, Inc. is a biotechnology company based in San Diego, California, focused on developing induced pluripotent stem cell therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018, the company aims to create patient-specific restorative cell therapies that can alter the progression of the disease. Its product pipeline includes ANPD001, an autologous neuron replacement therapy designed for sporadic Parkinson's disease, and ANPD002, a gene-edited version targeting familial forms of the disease. By integrating innovative genomic approaches with stem cell biology, Aspen Neuroscience seeks to advance the field of personalized medicine and improve treatment outcomes for patients suffering from Parkinson's disease.
Faraday Pharmaceuticals, Inc. is a biopharmaceutical company based in Seattle, Washington, that focuses on developing innovative therapies to treat ischemia-reperfusion injury, particularly following ST elevation myocardial infarction. Founded in 2014, the company has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements, which were developed in the laboratory of Dr. Mark Roth at the Fred Hutchinson Cancer Center. Faraday's therapeutics aim to utilize specific reduced forms of elements to enhance patient outcomes, providing medical practitioners with effective treatment options for ischemia-reperfusion injury and other critical care conditions.
Locanabio, Inc. develops RNA-targeted gene therapies to treat a spectrum of underserved diseases. It offers therapies for neuromuscular, neurodegeneration, and ophthalmology diseases. Locanabio, Inc. was formerly known as Locana, Inc. and changed its name to Locanabio, Inc. in July 2020. The company was founded in 2016 and is based in San Diego, California.
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines using its innovative base editing technology. This technology allows for targeted alterations of single bases in the genome without creating double-stranded breaks in DNA, representing a potential advancement in genetic therapies. The company's pipeline includes programs aimed at treating serious diseases such as sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, and pediatric acute myeloid leukemia, as well as conditions like alpha-1 antitrypsin deficiency and certain central nervous system disorders. Beam Therapeutics is committed to providing life-long cures through its various approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Founded in 2017, Beam continues to build collaborations to enhance its research and development efforts.
Sana Biotechnology is a biotechnology company focused on developing engineered cells as therapies for various diseases. Incorporated in 2018 and based in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company leverages recent scientific advancements to reprogram cells or replace damaged cells and tissues. Sana's mission is to create a new class of medicines that address unmet treatment needs across a wide range of therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Its pipeline includes several product candidates, such as SC291, SC262, SC255, and UP421, aimed at transforming the approach to disease treatment.
Glympse Bio, Inc. is focused on developing innovative diagnostic solutions that facilitate noninvasive monitoring of various diseases, including cancer, fibrosis, immunological disorders, and infectious diseases. The company employs modular nanoparticle sensors, utilizing precisely engineered diagnostic agents that assess disease states within the body and convey this information through urine analysis. This approach allows for predictive monitoring and evaluation of treatment responses. Founded in 2015 and based in Cambridge, Massachusetts, Glympse Bio's technology is rooted in research originally conducted at MIT and led by a team of experts in nanomedicine and biomedical engineering. Their flagship product, Glympse Inside, serves as a comprehensive platform for disease monitoring and aims to revolutionize how diseases are diagnosed and managed.
Magnolia Neurosciences Corporation is a New York-based company focused on drug discovery and development, specifically targeting neuroprotective therapies for central nervous system diseases and neurodegeneration. Established in 2018, the company aims to create proprietary small molecule therapeutics that prevent neuronal cell death, offering new treatment options for patients with neurodegenerative disorders and related conditions. Magnolia Neurosciences was founded to advance technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium. Through its innovative approach, the company seeks to address significant medical needs in the field of neurology.
Omniome, Inc. is a biotechnology company based in San Diego, California, established in 2013. It specializes in developing a proprietary DNA sequencing platform that aims to deliver high accuracy in sequencing results. The company employs its Sequencing By Binding technology, which enhances nucleotide and DNA matching by utilizing the natural matching capabilities of polymerase. This innovative approach not only provides precise and rapid results but also offers a cost-effective solution, which has the potential to significantly advance cancer diagnostics. Omniome is backed by prominent life sciences venture investors and is focused on becoming a trusted leader in the field of clinical sequencing.
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines using its innovative base editing technology. This technology allows for targeted alterations of single bases in the genome without creating double-stranded breaks in DNA, representing a potential advancement in genetic therapies. The company's pipeline includes programs aimed at treating serious diseases such as sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, and pediatric acute myeloid leukemia, as well as conditions like alpha-1 antitrypsin deficiency and certain central nervous system disorders. Beam Therapeutics is committed to providing life-long cures through its various approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Founded in 2017, Beam continues to build collaborations to enhance its research and development efforts.
Boragen Inc. is a biotechnology company based in Durham, North Carolina, that specializes in designing and developing multifunctional small molecule boron solutions for applications in crop protection, animal health, and human health. Founded in 2015, the company focuses on creating next-generation fungicides through its synthetic chemistry platforms, which aim to promote sustainable farming practices. Boragen's product pipeline includes BAG8, a boron-based multisite fungicide, and BN2266, which targets mRNA processing as a crop protection fungicide. Additionally, the company is developing a dual-function nematicide-fungicide designed for root protection and endo-parasiticides that address resistance challenges. Through its innovative approach, Boragen seeks to enhance agricultural efficiency while minimizing chemical usage.
ApoGen Biotechnologies, Inc. is focused on the development of new class of therapeutics targeting drivers of cancer genomic mutation.As the arsenal of available cancer therapies has grown and evolved from cytotoxic chemotherapy to targeted therapy to immunotherapy, one fact has unfortunately remained constant nearly all cancer drug therapies eventually fail due to the development of drug resistance. Mutation of cellular DNA is central to the formation of cancer, and chronic mutation of the cancer genome is a primary cause of cancer evolution and drug resistance, resulting in ineffective therapy, cancer recurrence and metastasis, and decreased overall survival.
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.
Unity Biotechnology is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing diseases associated with aging. The company specializes in clearing senescent cells through the creation of senolytic medicines, which target vulnerabilities specific to these cells while preserving normal ones. Its lead drug candidates include UBX0101, currently undergoing Phase II trials for musculoskeletal disorders and Phase Ib trials for moderate-to-severe knee osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is exploring treatments for various age-related conditions, including ophthalmologic, pulmonary, kidney, and liver diseases. Founded in 2009 and based in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. and rebranded in 2015.
Denali Therapeutics is a biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151, which are in various phases of clinical trials for Parkinson's disease. Additionally, Denali is developing DNL747, a selective RIPK1 inhibitor currently in Phase 1b trials for Alzheimer's and ALS. It also has programs focused on enzyme replacement therapy for MPS II and antibody transport vehicles targeting key proteins involved in neurodegeneration. Denali collaborates with various organizations, including Takeda Pharmaceutical Company and Genentech, to enhance its research efforts. Founded in 2013, Denali Therapeutics emphasizes a science-driven approach to address the complex challenges posed by neurodegenerative diseases, leveraging recent scientific insights and translational medicine tools.
Quanterix Corporation is a life sciences company focused on developing an advanced platform for single-molecule analysis, known for its ultra-sensitive digital immunoassay technology. This innovative approach enables precise detection and quantification of individual proteins and small molecules in complex biological samples, which is critical for clinical diagnostics, drug development, and life science research. Quanterix's flagship technology, Simoa, allows for the reliable measurement of protein biomarkers in extremely low concentrations, surpassing conventional immunoassay methods. The company offers a range of products, including assay kits, specialized assays for neurodegenerative diseases, and advanced instrumentation designed to enhance early disease detection and improve patient outcomes. Founded in 2007, Quanterix is supported by prominent life science investors, positioning it to address significant unmet medical needs and contribute to advancements in healthcare.
Faraday Pharmaceuticals, Inc. is a biopharmaceutical company based in Seattle, Washington, that focuses on developing innovative therapies to treat ischemia-reperfusion injury, particularly following ST elevation myocardial infarction. Founded in 2014, the company has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements, which were developed in the laboratory of Dr. Mark Roth at the Fred Hutchinson Cancer Center. Faraday's therapeutics aim to utilize specific reduced forms of elements to enhance patient outcomes, providing medical practitioners with effective treatment options for ischemia-reperfusion injury and other critical care conditions.
Denali Therapeutics is a biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151, which are in various phases of clinical trials for Parkinson's disease. Additionally, Denali is developing DNL747, a selective RIPK1 inhibitor currently in Phase 1b trials for Alzheimer's and ALS. It also has programs focused on enzyme replacement therapy for MPS II and antibody transport vehicles targeting key proteins involved in neurodegeneration. Denali collaborates with various organizations, including Takeda Pharmaceutical Company and Genentech, to enhance its research efforts. Founded in 2013, Denali Therapeutics emphasizes a science-driven approach to address the complex challenges posed by neurodegenerative diseases, leveraging recent scientific insights and translational medicine tools.
Unity Biotechnology is a biotechnology company dedicated to the research and development of therapeutics aimed at extending human health span by addressing diseases associated with aging. The company specializes in clearing senescent cells through the creation of senolytic medicines, which target vulnerabilities specific to these cells while preserving normal ones. Its lead drug candidates include UBX0101, currently undergoing Phase II trials for musculoskeletal disorders and Phase Ib trials for moderate-to-severe knee osteoarthritis, and UBX1325, which is in Phase I trials for diabetic macular edema. Additionally, Unity is exploring treatments for various age-related conditions, including ophthalmologic, pulmonary, kidney, and liver diseases. Founded in 2009 and based in South San Francisco, California, Unity Biotechnology was formerly known as Forge, Inc. and rebranded in 2015.
Faraday Pharmaceuticals, Inc. is a biopharmaceutical company based in Seattle, Washington, that focuses on developing innovative therapies to treat ischemia-reperfusion injury, particularly following ST elevation myocardial infarction. Founded in 2014, the company has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements, which were developed in the laboratory of Dr. Mark Roth at the Fred Hutchinson Cancer Center. Faraday's therapeutics aim to utilize specific reduced forms of elements to enhance patient outcomes, providing medical practitioners with effective treatment options for ischemia-reperfusion injury and other critical care conditions.
Siluria Technologies is a materials innovation company solving global challenges for partners in the natural gas, chemicals and fuel industries. Integrating nanotechnology, biotechnology and chemical engineering, Siluria has developed a solution to the grand challenge of efficient manufacturing: the ability to produce chemicals and fuels from a cheaper, more abundant resource than oil. The company's economically superior, energy-efficient platform converts natural gas into the same materials manufactured today using current industry infrastructure. Siluria's world-class R&D and engineering teams are rapidly commercializing the company's technology to pilot-scale production in close dialogue with the world's largest chemical and fuel companies.Siluria's backers include Alloy Ventures, ARCH Venture Partners, Kleiner Perkins Caufield & Byers, Altitude Life Science Ventures, Lux Capital, and Presidio Ventures.
Nanosys, Inc. specializes in developing and manufacturing quantum dot technology to enhance high-definition viewing experiences in the display industry. Founded in 2001 and based in Milpitas, California, the company offers a range of products, including Quantum Dot Concentrate material, quantum dot nanomaterials, and Quantum Dot Enhancement films. These products improve color performance and brightness in a variety of consumer electronics, such as tablets, televisions, smartphones, and automotive interiors. Nanosys' quantum dot technology is compatible with various display types, including LED-LCDs, OLEDs, and micro-LEDs, and has been integrated into over 20 million devices across more than 400 unique products. The company also explores applications of its nanotechnology in areas beyond displays, such as agriculture.
Quanterix Corporation is a life sciences company focused on developing an advanced platform for single-molecule analysis, known for its ultra-sensitive digital immunoassay technology. This innovative approach enables precise detection and quantification of individual proteins and small molecules in complex biological samples, which is critical for clinical diagnostics, drug development, and life science research. Quanterix's flagship technology, Simoa, allows for the reliable measurement of protein biomarkers in extremely low concentrations, surpassing conventional immunoassay methods. The company offers a range of products, including assay kits, specialized assays for neurodegenerative diseases, and advanced instrumentation designed to enhance early disease detection and improve patient outcomes. Founded in 2007, Quanterix is supported by prominent life science investors, positioning it to address significant unmet medical needs and contribute to advancements in healthcare.
Siluria Technologies is a materials innovation company solving global challenges for partners in the natural gas, chemicals and fuel industries. Integrating nanotechnology, biotechnology and chemical engineering, Siluria has developed a solution to the grand challenge of efficient manufacturing: the ability to produce chemicals and fuels from a cheaper, more abundant resource than oil. The company's economically superior, energy-efficient platform converts natural gas into the same materials manufactured today using current industry infrastructure. Siluria's world-class R&D and engineering teams are rapidly commercializing the company's technology to pilot-scale production in close dialogue with the world's largest chemical and fuel companies.Siluria's backers include Alloy Ventures, ARCH Venture Partners, Kleiner Perkins Caufield & Byers, Altitude Life Science Ventures, Lux Capital, and Presidio Ventures.
Cambrios Technologies Corp. develops electronic materials for the display industry. The company provides wet-processable transparent conductive films. Its nanostructured materials can be deposited using existing production equipment to achieve enhanced performance of display devices and components. The company was founded in 2002 as Semzyme, Inc. and changed its name to Cambrios Technologies Corp. in August 2004. Cambrios Technologies Corp. is based in Sunnyvale, California.
Permeon Biologics is focused on improving human health through its innovative Intraphilin Technology Platform. This platform identifies naturally occurring human proteins known for their ability to enhance cellular uptake and permeate cell membranes effectively. By leveraging these "supercharged proteins," Permeon Biologics aims to develop a new generation of therapeutic drugs that can deliver functional proteins capable of replacing or restoring defective cellular pathways associated with various diseases. This approach represents a significant advancement in the field of intracellular biologics, positioning the company at the forefront of therapeutic innovation.
Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.
Siluria Technologies is a materials innovation company solving global challenges for partners in the natural gas, chemicals and fuel industries. Integrating nanotechnology, biotechnology and chemical engineering, Siluria has developed a solution to the grand challenge of efficient manufacturing: the ability to produce chemicals and fuels from a cheaper, more abundant resource than oil. The company's economically superior, energy-efficient platform converts natural gas into the same materials manufactured today using current industry infrastructure. Siluria's world-class R&D and engineering teams are rapidly commercializing the company's technology to pilot-scale production in close dialogue with the world's largest chemical and fuel companies.Siluria's backers include Alloy Ventures, ARCH Venture Partners, Kleiner Perkins Caufield & Byers, Altitude Life Science Ventures, Lux Capital, and Presidio Ventures.
Shocking Technologies, Inc. started operations as a privately held, venture-backed company developing Voltage Switchable Dielectricâ„¢ (VSDâ„¢) materials. A VSDâ„¢ material is a polymer nano-composite that behaves like an insulator (dielectric) during normal circuit operation and becomes conductive when the voltage across the VSDâ„¢ material increases beyond a predefined threshold voltage. The voltage switches back to an insulator again after the voltage drops below the threshold. This unique property, coupled with the ability to tailor the response of the material, opens up several new areas in electronics. The first application being introduced enables embedded electrostatic discharge (ESD) protection in printed circuit boards (PCBs) and semiconductor packages. Subsequent applications will usher in new manufacturing processes as well as novel product designs.
Oncofactor is a Seattle, Washington-based developer of cancer therapeutics that disrupt signaling pathways between tumors and the immune system.
Siluria Technologies is a materials innovation company solving global challenges for partners in the natural gas, chemicals and fuel industries. Integrating nanotechnology, biotechnology and chemical engineering, Siluria has developed a solution to the grand challenge of efficient manufacturing: the ability to produce chemicals and fuels from a cheaper, more abundant resource than oil. The company's economically superior, energy-efficient platform converts natural gas into the same materials manufactured today using current industry infrastructure. Siluria's world-class R&D and engineering teams are rapidly commercializing the company's technology to pilot-scale production in close dialogue with the world's largest chemical and fuel companies.Siluria's backers include Alloy Ventures, ARCH Venture Partners, Kleiner Perkins Caufield & Byers, Altitude Life Science Ventures, Lux Capital, and Presidio Ventures.
Crystal IS specializes in the production of ultraviolet light emitting diodes (UV LEDs) utilizing single-crystal aluminum nitride (AlN) substrate technology. As a leader in this field, the company focuses on creating high-performance UVC LEDs designed for water, surface, and air purification applications. Their products cater to a wide range of sectors, including consumer and commercial appliances, medical devices, and life sciences. By emphasizing energy efficiency and durability, Crystal IS enables its clients to enhance their production with effective disinfection solutions.
BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing targeted and programmable therapeutics known as Accurins. These innovative therapeutics are engineered with specific physical and chemical properties to effectively target particular cells or tissues, allowing for the concentration of therapeutic agents at disease sites. This approach aims to enhance treatment efficacy while reducing adverse effects on healthy tissues. BIND Therapeutics primarily concentrates on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with biopharmaceutical firms to develop Accurins utilizing therapeutic payloads from their pipelines. Its operations extend to the United States and Russia, focusing on targeting tumors at tissue, cellular, and molecular levels.
Groove Biopharma focuses on the generation of novel microRNA (miRNA) therapeutics with improved properties, including higher potency and enhanced pharmacodynamic activity. Endogenous microRNAs (miRNAs) are involved in extensive regulatory networks for many target genes and pathways. Groove Biopharma’s core technology addresses a new avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA. Using exclusive technology, Groove Biopharma is generating a series of lead candidates with the potential to be best-in-class therapeutics. By incorporating proprietary structural modifications into miRNA therapeutics, the Groove Biopharma technology platform presents promising potential for treating a wide range of diseases, including cancer, fibrosis, and infectious disease.
Shocking Technologies, Inc. started operations as a privately held, venture-backed company developing Voltage Switchable Dielectricâ„¢ (VSDâ„¢) materials. A VSDâ„¢ material is a polymer nano-composite that behaves like an insulator (dielectric) during normal circuit operation and becomes conductive when the voltage across the VSDâ„¢ material increases beyond a predefined threshold voltage. The voltage switches back to an insulator again after the voltage drops below the threshold. This unique property, coupled with the ability to tailor the response of the material, opens up several new areas in electronics. The first application being introduced enables embedded electrostatic discharge (ESD) protection in printed circuit boards (PCBs) and semiconductor packages. Subsequent applications will usher in new manufacturing processes as well as novel product designs.
Innovalight, founded by Conrad Burke, specializes in the development of high-efficiency, low-cost solar modules utilizing a unique silicon ink technology. This innovative approach, which has been in development since 2005, allows for the processing of silicon in a liquid form, significantly enhancing the cost and efficiency of solar power generation. Innovalight's focus is on creating ultra-thin film power modules suitable for both residential and commercial applications, contributing to a manufacturing paradigm shift in the solar industry. By emphasizing the use of silicon-based solar cells, the company aims to improve the accessibility and effectiveness of grid-connected solar power solutions.
Cambrios Technologies Corp. develops electronic materials for the display industry. The company provides wet-processable transparent conductive films. Its nanostructured materials can be deposited using existing production equipment to achieve enhanced performance of display devices and components. The company was founded in 2002 as Semzyme, Inc. and changed its name to Cambrios Technologies Corp. in August 2004. Cambrios Technologies Corp. is based in Sunnyvale, California.
Innovalight, founded by Conrad Burke, specializes in the development of high-efficiency, low-cost solar modules utilizing a unique silicon ink technology. This innovative approach, which has been in development since 2005, allows for the processing of silicon in a liquid form, significantly enhancing the cost and efficiency of solar power generation. Innovalight's focus is on creating ultra-thin film power modules suitable for both residential and commercial applications, contributing to a manufacturing paradigm shift in the solar industry. By emphasizing the use of silicon-based solar cells, the company aims to improve the accessibility and effectiveness of grid-connected solar power solutions.
Shocking Technologies, Inc. started operations as a privately held, venture-backed company developing Voltage Switchable Dielectricâ„¢ (VSDâ„¢) materials. A VSDâ„¢ material is a polymer nano-composite that behaves like an insulator (dielectric) during normal circuit operation and becomes conductive when the voltage across the VSDâ„¢ material increases beyond a predefined threshold voltage. The voltage switches back to an insulator again after the voltage drops below the threshold. This unique property, coupled with the ability to tailor the response of the material, opens up several new areas in electronics. The first application being introduced enables embedded electrostatic discharge (ESD) protection in printed circuit boards (PCBs) and semiconductor packages. Subsequent applications will usher in new manufacturing processes as well as novel product designs.
Quanterix Corporation is a life sciences company focused on developing an advanced platform for single-molecule analysis, known for its ultra-sensitive digital immunoassay technology. This innovative approach enables precise detection and quantification of individual proteins and small molecules in complex biological samples, which is critical for clinical diagnostics, drug development, and life science research. Quanterix's flagship technology, Simoa, allows for the reliable measurement of protein biomarkers in extremely low concentrations, surpassing conventional immunoassay methods. The company offers a range of products, including assay kits, specialized assays for neurodegenerative diseases, and advanced instrumentation designed to enhance early disease detection and improve patient outcomes. Founded in 2007, Quanterix is supported by prominent life science investors, positioning it to address significant unmet medical needs and contribute to advancements in healthcare.
BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing targeted and programmable therapeutics known as Accurins. These innovative therapeutics are engineered with specific physical and chemical properties to effectively target particular cells or tissues, allowing for the concentration of therapeutic agents at disease sites. This approach aims to enhance treatment efficacy while reducing adverse effects on healthy tissues. BIND Therapeutics primarily concentrates on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with biopharmaceutical firms to develop Accurins utilizing therapeutic payloads from their pipelines. Its operations extend to the United States and Russia, focusing on targeting tumors at tissue, cellular, and molecular levels.
Ensemble Discovery is developing a new class of therapeutics - the Ensemblinsâ„¢, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. They have two complementary platforms that provide access to these molecules. Firstly, they use their proprietary DNA-Programmed Chemistryâ„¢ (DPCâ„¢) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, they have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.
Innovalight, founded by Conrad Burke, specializes in the development of high-efficiency, low-cost solar modules utilizing a unique silicon ink technology. This innovative approach, which has been in development since 2005, allows for the processing of silicon in a liquid form, significantly enhancing the cost and efficiency of solar power generation. Innovalight's focus is on creating ultra-thin film power modules suitable for both residential and commercial applications, contributing to a manufacturing paradigm shift in the solar industry. By emphasizing the use of silicon-based solar cells, the company aims to improve the accessibility and effectiveness of grid-connected solar power solutions.
Shocking Technologies, Inc. started operations as a privately held, venture-backed company developing Voltage Switchable Dielectricâ„¢ (VSDâ„¢) materials. A VSDâ„¢ material is a polymer nano-composite that behaves like an insulator (dielectric) during normal circuit operation and becomes conductive when the voltage across the VSDâ„¢ material increases beyond a predefined threshold voltage. The voltage switches back to an insulator again after the voltage drops below the threshold. This unique property, coupled with the ability to tailor the response of the material, opens up several new areas in electronics. The first application being introduced enables embedded electrostatic discharge (ESD) protection in printed circuit boards (PCBs) and semiconductor packages. Subsequent applications will usher in new manufacturing processes as well as novel product designs.
Cambrios Technologies Corp. develops electronic materials for the display industry. The company provides wet-processable transparent conductive films. Its nanostructured materials can be deposited using existing production equipment to achieve enhanced performance of display devices and components. The company was founded in 2002 as Semzyme, Inc. and changed its name to Cambrios Technologies Corp. in August 2004. Cambrios Technologies Corp. is based in Sunnyvale, California.
Ahura Scientific Inc. specializes in developing portable, ultra-compact optical systems designed for the immediate identification and authentication of liquid and solid chemical substances. The company’s handheld Raman spectrometers are particularly utilized for raw material identification and finished product authentication within the pharmaceutical and consumer health sectors. Additionally, its products serve critical functions in the identification of chemicals and explosives, material verification, anti-counterfeiting measures, and medical devices. Manufactured in the USA in an ISO 9001-certified facility, Ahura Scientific's offerings are recognized for their exceptional portability and performance, catering to a diverse clientele that includes agencies and companies across the homeland security, life sciences, industrial, and medical markets.
Crystal IS specializes in the production of ultraviolet light emitting diodes (UV LEDs) utilizing single-crystal aluminum nitride (AlN) substrate technology. As a leader in this field, the company focuses on creating high-performance UVC LEDs designed for water, surface, and air purification applications. Their products cater to a wide range of sectors, including consumer and commercial appliances, medical devices, and life sciences. By emphasizing energy efficiency and durability, Crystal IS enables its clients to enhance their production with effective disinfection solutions.
AmberWave, Inc., formerly AmberWave Systems Corporation, engages in the research, development, and licensing of technologies for semiconductor manufacturing. It provides Strained Silicon, a technology that is used in microchips to improve performance and decrease power consumption; and Aspect Ratio Trapping, a technology, which is used to make chips for silicon-based photonics and photovoltaic cells. The company was founded in 1998 and is headquartered in Salem, New Hampshire. AmberWave Systems Corporation is a former subsidiary of U.S. Robotics Corp.
Nitronex is a leading developer and manufacturer of gallium nitride-on-silicon (GaN-on-Si) RF power devices, specializing in high-performance semiconductors for various applications. Founded in 1999 by graduates of the wide bandgap program at North Carolina State University, the company is headquartered in Durham, North Carolina. Nitronex focuses on producing GaN-based RF power transistors that serve markets including wireless communications, broadband, and military applications. With a strong commitment to innovation, the company holds 21 patents and has an additional 17 patents pending, highlighting its role as a pioneer in the development of advanced semiconductor technology.
Innovalight, founded by Conrad Burke, specializes in the development of high-efficiency, low-cost solar modules utilizing a unique silicon ink technology. This innovative approach, which has been in development since 2005, allows for the processing of silicon in a liquid form, significantly enhancing the cost and efficiency of solar power generation. Innovalight's focus is on creating ultra-thin film power modules suitable for both residential and commercial applications, contributing to a manufacturing paradigm shift in the solar industry. By emphasizing the use of silicon-based solar cells, the company aims to improve the accessibility and effectiveness of grid-connected solar power solutions.
Amphora Discovery Corporation is a biotechnology company based in Durham, North Carolina, focused on providing integrated services to the pharmaceutical and biopharmaceutical industries. Founded in 2001, the company specializes in pathway-based drug discovery and offers a range of services, including in vitro assay protocols, high-throughput screening, compound profiling, custom assay development, and enzymology services. Amphora Discovery's lead generation platform is designed to deliver high precision, selectivity, and data quality, aiding in the development of proprietary clinical entities for various therapeutic areas, including oncology, inflammation, metabolic diseases, and neurological disorders. Notably, the company has advanced preclinical candidates targeting AKT1 and p38, which are specific inhibitors with potential applications in treating cancer and inflammatory conditions. As of 2008, Amphora operates as a subsidiary of Nanosyn Inc.
NeurogesX, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel non-opioid, pain management therapies to address unmet medical needs. The company was formerly known as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in September 2000. NeurogesX, Inc. was founded in 1998 and is based in San Mateo, California.
Amphora Discovery Corporation is a biotechnology company based in Durham, North Carolina, focused on providing integrated services to the pharmaceutical and biopharmaceutical industries. Founded in 2001, the company specializes in pathway-based drug discovery and offers a range of services, including in vitro assay protocols, high-throughput screening, compound profiling, custom assay development, and enzymology services. Amphora Discovery's lead generation platform is designed to deliver high precision, selectivity, and data quality, aiding in the development of proprietary clinical entities for various therapeutic areas, including oncology, inflammation, metabolic diseases, and neurological disorders. Notably, the company has advanced preclinical candidates targeting AKT1 and p38, which are specific inhibitors with potential applications in treating cancer and inflammatory conditions. As of 2008, Amphora operates as a subsidiary of Nanosyn Inc.
Cambrios Technologies Corp. develops electronic materials for the display industry. The company provides wet-processable transparent conductive films. Its nanostructured materials can be deposited using existing production equipment to achieve enhanced performance of display devices and components. The company was founded in 2002 as Semzyme, Inc. and changed its name to Cambrios Technologies Corp. in August 2004. Cambrios Technologies Corp. is based in Sunnyvale, California.
Ahura Scientific Inc. specializes in developing portable, ultra-compact optical systems designed for the immediate identification and authentication of liquid and solid chemical substances. The company’s handheld Raman spectrometers are particularly utilized for raw material identification and finished product authentication within the pharmaceutical and consumer health sectors. Additionally, its products serve critical functions in the identification of chemicals and explosives, material verification, anti-counterfeiting measures, and medical devices. Manufactured in the USA in an ISO 9001-certified facility, Ahura Scientific's offerings are recognized for their exceptional portability and performance, catering to a diverse clientele that includes agencies and companies across the homeland security, life sciences, industrial, and medical markets.
Amphora Discovery Corporation is a biotechnology company based in Durham, North Carolina, focused on providing integrated services to the pharmaceutical and biopharmaceutical industries. Founded in 2001, the company specializes in pathway-based drug discovery and offers a range of services, including in vitro assay protocols, high-throughput screening, compound profiling, custom assay development, and enzymology services. Amphora Discovery's lead generation platform is designed to deliver high precision, selectivity, and data quality, aiding in the development of proprietary clinical entities for various therapeutic areas, including oncology, inflammation, metabolic diseases, and neurological disorders. Notably, the company has advanced preclinical candidates targeting AKT1 and p38, which are specific inhibitors with potential applications in treating cancer and inflammatory conditions. As of 2008, Amphora operates as a subsidiary of Nanosyn Inc.
Nura, Inc. is focused on discovering and developing pharmaceuticals aimed at treating neurodegenerative diseases and behavioral disorders. The company specializes in therapeutics that target G Protein-coupled receptors (GPCR) and phosphodiesterase (PDE) enzymes expressed in the brain. Nura’s research includes programs for conditions such as Parkinson's disease, Alzheimer's disease, schizophrenia, depression, anxiety, obesity, and addiction, as well as attention-deficit hyperactivity disorder and pain. Through its innovative approach, Nura aims to address significant unmet medical needs in these areas.
Cambrios Technologies Corp. develops electronic materials for the display industry. The company provides wet-processable transparent conductive films. Its nanostructured materials can be deposited using existing production equipment to achieve enhanced performance of display devices and components. The company was founded in 2002 as Semzyme, Inc. and changed its name to Cambrios Technologies Corp. in August 2004. Cambrios Technologies Corp. is based in Sunnyvale, California.
AmberWave, Inc., formerly AmberWave Systems Corporation, engages in the research, development, and licensing of technologies for semiconductor manufacturing. It provides Strained Silicon, a technology that is used in microchips to improve performance and decrease power consumption; and Aspect Ratio Trapping, a technology, which is used to make chips for silicon-based photonics and photovoltaic cells. The company was founded in 1998 and is headquartered in Salem, New Hampshire. AmberWave Systems Corporation is a former subsidiary of U.S. Robotics Corp.
Ensemble Discovery is developing a new class of therapeutics - the Ensemblinsâ„¢, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. They have two complementary platforms that provide access to these molecules. Firstly, they use their proprietary DNA-Programmed Chemistryâ„¢ (DPCâ„¢) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, they have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.
NeurogesX, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel non-opioid, pain management therapies to address unmet medical needs. The company was formerly known as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in September 2000. NeurogesX, Inc. was founded in 1998 and is based in San Mateo, California.
Amphora Discovery Corporation is a biotechnology company based in Durham, North Carolina, focused on providing integrated services to the pharmaceutical and biopharmaceutical industries. Founded in 2001, the company specializes in pathway-based drug discovery and offers a range of services, including in vitro assay protocols, high-throughput screening, compound profiling, custom assay development, and enzymology services. Amphora Discovery's lead generation platform is designed to deliver high precision, selectivity, and data quality, aiding in the development of proprietary clinical entities for various therapeutic areas, including oncology, inflammation, metabolic diseases, and neurological disorders. Notably, the company has advanced preclinical candidates targeting AKT1 and p38, which are specific inhibitors with potential applications in treating cancer and inflammatory conditions. As of 2008, Amphora operates as a subsidiary of Nanosyn Inc.
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. Its innovative pipeline targets a range of serious conditions, including genetic disorders, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system and ocular diseases. The company has successfully brought several RNAi therapeutics to market, including ONPATTRO for hereditary transthyretin-mediated amyloidosis and GIVLAARI for acute hepatic porphyria. Additionally, Alnylam is advancing other investigational therapies, such as givosiran for acute hepatic porphyria and lumasiran for primary hyperoxaluria type 1. The company collaborates with various partners, including Sanofi Genzyme and Vir Biotechnology, to enhance its research and development efforts. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals aims to transform treatment approaches for patients with rare and debilitating diseases through its RNAi technology.
Amphora Discovery Corporation is a biotechnology company based in Durham, North Carolina, focused on providing integrated services to the pharmaceutical and biopharmaceutical industries. Founded in 2001, the company specializes in pathway-based drug discovery and offers a range of services, including in vitro assay protocols, high-throughput screening, compound profiling, custom assay development, and enzymology services. Amphora Discovery's lead generation platform is designed to deliver high precision, selectivity, and data quality, aiding in the development of proprietary clinical entities for various therapeutic areas, including oncology, inflammation, metabolic diseases, and neurological disorders. Notably, the company has advanced preclinical candidates targeting AKT1 and p38, which are specific inhibitors with potential applications in treating cancer and inflammatory conditions. As of 2008, Amphora operates as a subsidiary of Nanosyn Inc.
Ahura Scientific Inc. specializes in developing portable, ultra-compact optical systems designed for the immediate identification and authentication of liquid and solid chemical substances. The company’s handheld Raman spectrometers are particularly utilized for raw material identification and finished product authentication within the pharmaceutical and consumer health sectors. Additionally, its products serve critical functions in the identification of chemicals and explosives, material verification, anti-counterfeiting measures, and medical devices. Manufactured in the USA in an ISO 9001-certified facility, Ahura Scientific's offerings are recognized for their exceptional portability and performance, catering to a diverse clientele that includes agencies and companies across the homeland security, life sciences, industrial, and medical markets.
Nanosys, Inc. specializes in developing and manufacturing quantum dot technology to enhance high-definition viewing experiences in the display industry. Founded in 2001 and based in Milpitas, California, the company offers a range of products, including Quantum Dot Concentrate material, quantum dot nanomaterials, and Quantum Dot Enhancement films. These products improve color performance and brightness in a variety of consumer electronics, such as tablets, televisions, smartphones, and automotive interiors. Nanosys' quantum dot technology is compatible with various display types, including LED-LCDs, OLEDs, and micro-LEDs, and has been integrated into over 20 million devices across more than 400 unique products. The company also explores applications of its nanotechnology in areas beyond displays, such as agriculture.
NeurogesX, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel non-opioid, pain management therapies to address unmet medical needs. The company was formerly known as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in September 2000. NeurogesX, Inc. was founded in 1998 and is based in San Mateo, California.
AmberWave, Inc., formerly AmberWave Systems Corporation, engages in the research, development, and licensing of technologies for semiconductor manufacturing. It provides Strained Silicon, a technology that is used in microchips to improve performance and decrease power consumption; and Aspect Ratio Trapping, a technology, which is used to make chips for silicon-based photonics and photovoltaic cells. The company was founded in 1998 and is headquartered in Salem, New Hampshire. AmberWave Systems Corporation is a former subsidiary of U.S. Robotics Corp.
AmberWave, Inc., formerly AmberWave Systems Corporation, engages in the research, development, and licensing of technologies for semiconductor manufacturing. It provides Strained Silicon, a technology that is used in microchips to improve performance and decrease power consumption; and Aspect Ratio Trapping, a technology, which is used to make chips for silicon-based photonics and photovoltaic cells. The company was founded in 1998 and is headquartered in Salem, New Hampshire. AmberWave Systems Corporation is a former subsidiary of U.S. Robotics Corp.
Nanosys, Inc. specializes in developing and manufacturing quantum dot technology to enhance high-definition viewing experiences in the display industry. Founded in 2001 and based in Milpitas, California, the company offers a range of products, including Quantum Dot Concentrate material, quantum dot nanomaterials, and Quantum Dot Enhancement films. These products improve color performance and brightness in a variety of consumer electronics, such as tablets, televisions, smartphones, and automotive interiors. Nanosys' quantum dot technology is compatible with various display types, including LED-LCDs, OLEDs, and micro-LEDs, and has been integrated into over 20 million devices across more than 400 unique products. The company also explores applications of its nanotechnology in areas beyond displays, such as agriculture.
Amphora Discovery Corporation is a biotechnology company based in Durham, North Carolina, focused on providing integrated services to the pharmaceutical and biopharmaceutical industries. Founded in 2001, the company specializes in pathway-based drug discovery and offers a range of services, including in vitro assay protocols, high-throughput screening, compound profiling, custom assay development, and enzymology services. Amphora Discovery's lead generation platform is designed to deliver high precision, selectivity, and data quality, aiding in the development of proprietary clinical entities for various therapeutic areas, including oncology, inflammation, metabolic diseases, and neurological disorders. Notably, the company has advanced preclinical candidates targeting AKT1 and p38, which are specific inhibitors with potential applications in treating cancer and inflammatory conditions. As of 2008, Amphora operates as a subsidiary of Nanosyn Inc.
NeurogesX, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel non-opioid, pain management therapies to address unmet medical needs. The company was formerly known as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in September 2000. NeurogesX, Inc. was founded in 1998 and is based in San Mateo, California.
Nimble Technology is an information technology company that is focused on the development of enterprise information integration solutions. It offers a data integration platform that is able to utilize XQuery to build web services and applications such as enterprise information portals and business intelligence systems. Nimble Technology was acquired by Actuate in July 2003. Nimble Technology was founded in 1999.
New Era of Networks
Series C in 1996
New Era Technologies is a U.S.-based R&D technology company. The company develops markets and supports application integration software and provides application integration services. The company’s main product is NeoNet, software that facilitates the rapid and efficient deployment and ongoing maintenance of application integration across the enterprise. The company was acquired by Sybase in 2001. The company was founded in 1995 and is based in Colorado.
New Era of Networks
Series B in 1995
New Era Technologies is a U.S.-based R&D technology company. The company develops markets and supports application integration software and provides application integration services. The company’s main product is NeoNet, software that facilitates the rapid and efficient deployment and ongoing maintenance of application integration across the enterprise. The company was acquired by Sybase in 2001. The company was founded in 1995 and is based in Colorado.
New Era of Networks
Series A in 1995
New Era Technologies is a U.S.-based R&D technology company. The company develops markets and supports application integration software and provides application integration services. The company’s main product is NeoNet, software that facilitates the rapid and efficient deployment and ongoing maintenance of application integration across the enterprise. The company was acquired by Sybase in 2001. The company was founded in 1995 and is based in Colorado.
Nanophase Technologies Corporation, a skin and sun care focused company, provides engineered materials, formulation development, and commercial manufacturing with an integrated family of technologies in North America and internationally. It offers surface engineered zinc oxide and titanium dioxide for sunscreens and personal care products; fully formulated cosmetics under the Solésence brand name; and advanced materials products, such as architectural coatings, industrial coatings, abrasion-resistant additives, plastics additives, medical diagnostics, and various surface finishing technologies applications. The company was founded in 1989 and is headquartered in Romeoville, Illinois.